Atezolizumab +/- Bevacizumab for Alveolar Soft Part Sarcoma
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, certain medications like systemic immunosuppressive drugs and some investigational agents must be stopped before starting the trial. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug Atezolizumab +/- Bevacizumab for Alveolar Soft Part Sarcoma?
Is the combination of Atezolizumab and Bevacizumab safe for humans?
Atezolizumab (Tecentriq) and Bevacizumab (Avastin) have been studied for safety in various conditions. Atezolizumab is approved for use in certain cancers, and Bevacizumab has shown safety in treating a 90-year-old patient with alveolar soft part sarcoma, resulting in improved symptoms and disease response.12456
How is the drug combination of Atezolizumab and Bevacizumab unique for treating alveolar soft part sarcoma?
The combination of Atezolizumab (an immune checkpoint inhibitor) and Bevacizumab (a drug targeting blood vessel growth) is unique for treating alveolar soft part sarcoma because it combines immune system activation with inhibition of blood supply to the tumor, offering a novel approach for a condition that is typically resistant to standard chemotherapy.12345
What is the purpose of this trial?
This phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body (advanced) and cannot be removed by surgery (unresectable). Atezolizumab works by unblocking the immune system, allowing the immune system cells to recognize and then attack tumor cells. Bevacizumab works by controlling the growth of new blood vessels. Giving atezolizumab alone or atezolizumab with bevacizumab may shrink the cancer.
Research Team
Alice P Chen
Principal Investigator
National Cancer Institute LAO
Eligibility Criteria
This trial is for people with advanced alveolar soft part sarcoma that can't be removed by surgery. Participants must have certain blood cell counts, organ function levels, and a life expectancy over 3 months. They should not have had recent severe infections or major surgeries, and cannot be pregnant or breastfeeding. Adults and children over 2 years old may join; however, only adults can receive the combination treatment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive atezolizumab or atezolizumab plus bevacizumab intravenously every 21 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants who are progression-free at the end of a 2-year treatment holiday are followed every 6 months
Treatment Details
Interventions
- Atezolizumab
- Bevacizumab
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor